|
17 Mar 2023 |
Matrivax Initiates Phase 1 Clinical Development of MVX01, a Novel Pneumococcal Vaccine Candidate
|
|
15 Mar 2023 |
GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate
|
|
08 Mar 2023 |
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
|
|
22 Feb 2023 |
LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate
|
|
21 Feb 2023 |
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
|
|
21 Feb 2023 |
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
|
|
20 Feb 2023 |
Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
|
|
20 Feb 2023 |
FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review
|
|
17 Feb 2023 |
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
|
|
17 Feb 2023 |
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
|
|
16 Feb 2023 |
Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
|
|
14 Feb 2023 |
Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND submission
|
|
10 Feb 2023 |
Vaxxas Initiates Phase I Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent (IIV4) Delivered Using High-Density Microarray Patch (HD-MAP)
|
|
07 Feb 2023 |
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson's Disease
|
|
03 Feb 2023 |
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
|
|
30 Jan 2023 |
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
|
|
26 Jan 2023 |
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
|
|
25 Jan 2023 |
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
|
|
25 Jan 2023 |
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
|
|
20 Jan 2023 |
LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer
|
|
18 Jan 2023 |
Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
|
|
18 Jan 2023 |
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
|
|
16 Jan 2023 |
Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®
|
|
13 Jan 2023 |
Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines
|
|
10 Jan 2023 |
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
|
